George R. Stark

Cleveland Clinic — United States

Medicine · Health Sciences

120h-index65.0kcitations472works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(129), interferon and immune responses(99), NF-κB Signaling Pathways(71), Cancer-related Molecular Pathways(51), Immune Response and Inflammation(34)

Publications472 total

0644 Antiseptic treatment improves response to topical imiquimod therapy in a UVB-induced non-melanoma skin cancer murine model
Journal of Investigative Dermatology·2025
LB1220 The role of the microbiome in topical treatment efficacy for non-melanoma skin cancer in a UV-induced non-melanoma skin cancer mouse model
Journal of Investigative Dermatology·2025
Immunometabolic chaos in septic shock
Journal of Leukocyte Biology·2024· 2 citedOpen Access
Ammonia transporter RhBG initiates downstream signaling and functional responses by activating NFκB
Proceedings of the National Academy of Sciences·2024· 3 citedOpen Access
817 Topical PALA has greater therapeutic efficacy and fewer side effects than standards of care in a UV-induced non-melanoma skin cancer mouse model
Journal of Investigative Dermatology·2024Open Access
494 Impact of topical therapeutics for non-melanoma skin cancer on the cutaneous microbiome
Journal of Investigative Dermatology·2024Open Access
Topical <i>N</i>‐phosphonacetyl‐<scp>l</scp>‐aspartate is a dual action candidate for treating non‐melanoma skin cancer
Experimental Dermatology·2023· 4 citedOpen Access
STAT2 hinders STING intracellular trafficking and reshapes its activation in response to DNA damage
Proceedings of the National Academy of Sciences·2023· 17 citedOpen Access
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
Data from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
Data from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
2023Open Access
page 1 of 24Next →

Frequent Co-authors

Geoffrey M. Wahl(5), Xiaoxia Li(5), James Darnell(4), Ian M. Kerr(4), HyeonJoo Cheon(4), Chilakamarti V. Ramana(4), lan M. Kerr(3), Robert D. Schreiber(3), Jinbo Yang(3), Moitreyee Chatterjee‐Kishore(3), Hannah Nguyen(3), Bryan Williams(2), Robert H. Silverman(2), James C. Alwine(2), William R. Taylor(2), Richard L. Friedman(2), Jaime Renart(2), Jakob Reiser(2), Nywana Sizemore(2), Stewart Leung(2)